Edward J Miller

List of Publications by Year
in descending order

107 papers	6,134 citations	94381 37 h-index	71651 76 g-index
119 all docs	119 docs citations	119 times ranked	6134 citing authors

#	Article	IF	Citations
1	Nonbiopsy Diagnosis of Cardiac Transthyretin Amyloidosis. Circulation, 2016, 133, 2404-2412.	1.6	1,335
2	Macrophage migration inhibitory factor stimulates AMP-activated protein kinase in the ischaemic heart. Nature, 2008, 451, 578-582.	13.7	392
3	Multicenter Study of Planar Technetium 99m Pyrophosphate Cardiac Imaging. JAMA Cardiology, 2016, 1, 880.	3.0	304
4	Deep Learning for Prediction of Obstructive Disease From Fast Myocardial Perfusion SPECT. JACC: Cardiovascular Imaging, 2018, 11, 1654-1663.	2.3	246
5	ASNC/AHA/ASE/EANM/HFSA/ISA/SCMR/SNMMI expert consensus recommendations for multimodality imaging in cardiac amyloidosis: Part 1 of 2â€"evidence base and standardized methods of imaging. Journal of Nuclear Cardiology, 2019, 26, 2065-2123.	1.4	230
6	AMP-Activated Protein Kinase Activates p38 Mitogen-Activated Protein Kinase by Increasing Recruitment of p38 MAPK to TAB1 in the Ischemic Heart. Circulation Research, 2005, 97, 872-879.	2.0	210
7	Joint SNMMIâ€"ASNC Expert Consensus Document on the Role of ¹⁸F-FDG PET/CT in Cardiac Sarcoid Detection and Therapy Monitoring. Journal of Nuclear Medicine, 2017, 58, 1341-1353.	2.8	187
8	Quantitative interpretation of FDG PET/CT with myocardial perfusion imaging increases diagnostic information in the evaluation of cardiac sarcoidosis. Journal of Nuclear Cardiology, 2014, 21, 925-939.	1.4	155
9	A small molecule AMPK activator protects the heart against ischemiaâ€"reperfusion injury. Journal of Molecular and Cellular Cardiology, 2011, 51, 24-32.	0.9	149
10	Joint SNMMIâ€"ASNC expert consensus document on the role of 18F-FDG PET/CT in cardiac sarcoid detection and therapy monitoring. Journal of Nuclear Cardiology, 2017, 24, 1741-1758.	1.4	132
11	Deep Learning Analysis of Upright-Supine High-Efficiency SPECT Myocardial Perfusion Imaging for Prediction of Obstructive Coronary Artery Disease: A Multicenter Study. Journal of Nuclear Medicine, 2019, 60, 664-670.	2.8	113
12	ASNC/AHA/ASE/EANM/HFSA/ISA/SCMR/SNMMI Expert Consensus Recommendations for Multimodality Imaging in Cardiac Amyloidosis: Part 1 of 2â€"Evidence Base and Standardized Methods of Imaging. Journal of Cardiac Failure, 2019, 25, e1-e39.	0.7	107
13	Patient-centered imaging. Journal of Nuclear Cardiology, 2012, 19, 185-215.	1.4	106
14	The Polyphenols Resveratrol and S17834 Prevent the Structural and Functional Sequelae of Diet-Induced Metabolic Heart Disease in Mice. Circulation, 2012, 125, 1757-1764.	1.6	103
15	A joint procedural position statement on imaging in cardiac sarcoidosis: from the Cardiovascular and Inflammation & Infection Committees of the European Association of Nuclear Medicine, the European Association of Cardiovascular Imaging, and the American Society of Nuclear Cardiology. Journal of Nuclear Cardiology, 2018, 25, 298-319.	1.4	97
16	ASNC/AHA/ASE/EANM/HFSA/ISA/SCMR/SNMMI expert consensus recommendations for multimodality imaging in cardiac amyloidosis: Part 2 of 2â€"Diagnostic criteria and appropriate utilization. Journal of Nuclear Cardiology, 2020, 27, 659-673.	1.4	97
17	Dual Mechanisms Regulating AMPK Kinase Action in the Ischemic Heart. Circulation Research, 2005, 96, 337-345.	2.0	95
18	AMPâ€activated protein kinase: a core signalling pathway in the heart. Acta Physiologica, 2009, 196, 37-53.	1.8	86

#	Article	IF	Citations
19	Mitochondrial Reactive Oxygen Species Mediate Cardiac Structural, Functional, and Mitochondrial Consequences of Dietâ€Induced Metabolic Heart Disease. Journal of the American Heart Association, 2016, 5, .	1.6	85
20	Practicing Internal Medicine Onboard the USNS COMFORT in the Aftermath of the Haitian Earthquake. Annals of Internal Medicine, 2010, 152, 733.	2.0	76
21	A joint procedural position statement on imaging in cardiac sarcoidosis: from the Cardiovascular and Inflammation & Infection Committees of the European Association of Nuclear Medicine, the European Association of Cardiovascular Imaging, and the American Society of Nuclear Cardiology. European Heart Journal Cardiovascular Imaging, 2017, 18, 1073-1089.	0.5	74
22	Rationale and design of the REgistry of Fast Myocardial Perfusion Imaging with NExt generation SPECT (REFINE SPECT). Journal of Nuclear Cardiology, 2020, 27, 1010-1021.	1.4	74
23	The response of FDG uptake to immunosuppressive treatment on FDG PET/CT imaging for cardiac sarcoidosis. Journal of Nuclear Cardiology, 2017, 24, 413-424.	1.4	71
24	ASNC/AHA/ASE/EANM/HFSA/ISA/SCMR/SNMMI Expert Consensus Recommendations for Multimodality Imaging in Cardiac Amyloidosis: Part 2 of 2â€"Diagnostic Criteria and Appropriate Utilization. Journal of Cardiac Failure, 2019, 25, 854-865.	0.7	70
25	5-Year Prognostic Value of QuantitativeÂVersus Visual MPI in SubtleÂPerfusionÂDefects. JACC: Cardiovascular Imaging, 2020, 13, 774-785.	2.3	70
26	Machine learning predicts per-vessel early coronary revascularization after fast myocardial perfusion SPECT: results from multicentre REFINE SPECT registry. European Heart Journal Cardiovascular Imaging, 2020, 21, 549-559.	0.5	70
27	High fat, high sucrose diet causes cardiac mitochondrial dysfunction due in part to oxidative post-translational modification of mitochondrial complex II. Journal of Molecular and Cellular Cardiology, 2015, 78, 165-173.	0.9	68
28	AMPK deficiency in cardiac muscle results in dilated cardiomyopathy in the absence of changes in energy metabolism. Cardiovascular Research, 2015, 107, 235-245.	1.8	67
29	Longitudinal systolic strain, cardiac function improvement, and survival following treatment of light-chain (AL) cardiac amyloidosis. European Heart Journal Cardiovascular Imaging, 2017, 18, 1057-1064.	0.5	60
30	Activation of AMPK Î±- and Î³-isoform complexes in the intact ischemic rat heart. American Journal of Physiology - Heart and Circulatory Physiology, 2006, 291, H1927-H1934.	1.5	59
31	Can 99mTc-Pyrophosphate Aid in Early Detection of Cardiac Involvement in Asymptomatic Variant TTR Amyloidosis?. JACC: Cardiovascular Imaging, 2017, 10, 713-714.	2.3	55
32	Mitochondrial remodeling in mice with cardiomyocyte-specific lipid overload. Journal of Molecular and Cellular Cardiology, 2015, 79, 275-283.	0.9	52
33	Treatment of Multiorgan Sarcoidosis With Tofacitinib. ACR Open Rheumatology, 2020, 2, 106-109.	0.9	51
34	ASNC/AHA/ASE/EANM/HFSA/ISA/SCMR/SNMMI Expert Consensus Recommendations for Multimodality Imaging in Cardiac Amyloidosis: Part 1 of 2â€"Evidence Base and Standardized Methods of Imaging. Circulation: Cardiovascular Imaging, 2021, 14, e000029.	1.3	48
35	Preclinical Left Ventricular Diastolic Dysfunction in Metabolic Syndrome. American Journal of Cardiology, 2014, 114, 838-842.	0.7	46
36	InÂVivo Reactive Oxygen Species Detection With a Novel Positron Emission Tomography Tracer, 18F-DHMT, Allows for Early Detection of Anthracycline-Induced Cardiotoxicity in Rodents. JACC Basic To Translational Science, 2018, 3, 378-390.	1.9	46

#	Article	IF	Citations
37	Clinical Deployment of Explainable Artificial Intelligence of SPECT for Diagnosis of Coronary Artery Disease. JACC: Cardiovascular Imaging, 2022, 15, 1091-1102.	2.3	44
38	Inhibition of type 1 immunity with tofacitinib is associated with marked improvement in longstanding sarcoidosis. Nature Communications, 2022, 13, .	5.8	39
39	Serial Assessment of Coronary Flow Reserve by Rubidium-82 Positron Emission Tomography Predicts Mortality in Heart Transplant Recipients. JACC: Cardiovascular Imaging, 2020, 13, 109-120.	2.3	38
40	Prognostically safe stress-only single-photon emission computed tomography myocardial perfusion imaging guided by machine learning: report from REFINE SPECT. European Heart Journal Cardiovascular Imaging, 2021, 22, 705-714.	0.5	38
41	Scadding revisited: a proposed staging system for cardiac sarcoidosis. Sarcoidosis Vasculitis and Diffuse Lung Diseases, 2014, 31, 2-5.	0.2	36
42	Urocortin 2 autocrine/paracrine and pharmacologic effects to activate AMP-activated protein kinase in the heart. Proceedings of the National Academy of Sciences of the United States of America, 2013, 110, 16133-16138.	3.3	35
43	Addendum to ASNC/AHA/ASE/EANM/HFSA/ISA/SCMR/SNMMI expert consensus recommendations for multimodality imaging in cardiac amyloidosis: Part 1 of 2â€"evidence base and standardized methods of imaging. Journal of Nuclear Cardiology, 2021, 28, 1769-1774.	1.4	34
44	Time Course of Common Clinical Manifestations in Patients with Transthyretin Cardiac Amyloidosis: Delay From Symptom Onset to Diagnosis. Journal of Cardiac Failure, 2018, 24, 131-133.	0.7	28
45	Impact of Early Revascularization on Major Adverse Cardiovascular Events inÂRelation to Automatically QuantifiedÂIschemia. JACC: Cardiovascular Imaging, 2021, 14, 644-653.	2.3	28
46	National patterns in imaging utilization for diagnosis of cardiac amyloidosis: A focus on Tc99m-pyrophosphate scintigraphy. Journal of Nuclear Cardiology, 2017, 24, 1094-1097.	1.4	27
47	Determining a minimum set of variables for machine learning cardiovascular event prediction: results from REFINE SPECT registry. Cardiovascular Research, 2022, 118, 2152-2164.	1.8	26
48	Visual identification of coronary calcifications on attenuation correction CT improves diagnostic accuracy of SPECT/CT myocardial perfusion imaging. Journal of Nuclear Cardiology, 2017, 24, 711-720.	1.4	23
49	Repeatability and Optimization of FDGÂPositron Emission Tomography forÂEvaluation of Cardiac Sarcoidosis. JACC: Cardiovascular Imaging, 2019, 12, 1284-1287.	2.3	23
50	Diagnostic accuracy of stress-only myocardial perfusion SPECT improved by deep learning. European Journal of Nuclear Medicine and Molecular Imaging, 2021, 48, 2793-2800.	3.3	23
51	Myocardial Ischemic Burden and Differences in Prognosis Among Patients With and Without Diabetes: Results From the Multicenter International REFINE SPECT Registry. Diabetes Care, 2020, 43, 453-459.	4.3	21
52	Transient ischaemic dilation and post-stress wall motion abnormality increase risk in patients with less than moderate ischaemia: analysis of the REFINE SPECT registry. European Heart Journal Cardiovascular Imaging, 2020, 21, 567-575.	0.5	21
53	Diagnostic safety of a machine learning-based automatic patient selection algorithm for stress-only myocardial perfusion SPECT. Journal of Nuclear Cardiology, 2022, 29, 2295-2307.	1.4	21
54	Survival Following Implantable Cardioverterâ€Defibrillator Implantation in Patients With Amyloid Cardiomyopathy. Journal of the American Heart Association, 2020, 9, e016038.	1.6	19

#	Article	IF	Citations
55	A novel LKB1 isoform enhances AMPK metabolic activity and displays oncogenic properties. Oncogene, 2015, 34, 2337-2346.	2.6	18
56	Upper reference limits of transient ischemic dilation ratio for different protocols on new-generation cadmium zinc telluride cameras: A report from REFINE SPECT registry. Journal of Nuclear Cardiology, 2020, 27, 1180-1189.	1.4	17
57	A phenomapping-derived tool to personalize the selection of anatomical vs. functional testing in evaluating chest pain (ASSIST). European Heart Journal, 2021, 42, 2536-2548.	1.0	17
58	PET-Based Imaging of Ischemic Heart Disease. PET Clinics, 2019, 14, 211-221.	1.5	16
59	ASNC/AHA/ASE/EANM/HFSA/ISA/SCMR/SNMMI Expert Consensus Recommendations for Multimodality Imaging in Cardiac Amyloidosis: Part 2 of 2â€"Diagnostic Criteria and Appropriate Utilization. Circulation: Cardiovascular Imaging, 2021, 14, e000030.	1.3	16
60	Infusion of a biotinylated bis-glucose photolabel: a new method to quantify cell surface GLUT4 in the intact mouse heart. American Journal of Physiology - Endocrinology and Metabolism, 2007, 292, E1922-E1928.	1.8	15
61	Arrhythmias in Cardiac Sarcoidosis Bench to Bedside. Circulation: Arrhythmia and Electrophysiology, 2021, 14, e009203.	2.1	14
62	Handling missing values in machine learning to predict patient-specific risk of adverse cardiac events: Insights from REFINE SPECT registry. Computers in Biology and Medicine, 2022, 145, 105449.	3.9	14
63	Advances in PET-Based Cardiac Amyloid Radiotracers. Current Cardiology Reports, 2020, 22, 40.	1.3	13
64	Prognostic Value of Phase Analysis for Predicting Adverse Cardiac Events Beyond Conventional Single-Photon Emission Computed Tomography Variables: Results From the REFINE SPECT Registry. Circulation: Cardiovascular Imaging, 2021, 14, e012386.	1.3	13
65	Establishing an Evidence-Based Method to Diagnose Cardiac Sarcoidosis. Circulation: Cardiovascular Imaging, 2018, 11, e007408.	1.3	11
66	Automated quantitative analysis of CZT SPECT stratifies cardiovascular risk in the obese population: Analysis of the REFINE SPECT registry. Journal of Nuclear Cardiology, 2022, 29, 727-736.	1.4	11
67	Nuclear Tracers for Transthyretin Cardiac Amyloidosis. Circulation: Cardiovascular Imaging, 2013, 6, 162-164.	1.3	9
68	Up-regulation of Intracellular Calcium Handling Underlies the Recovery of Endotoxemic Cardiomyopathy in Mice. Anesthesiology, 2017, 126, 1125-1138.	1.3	8
69	Addendum to ASNC/AHA/ASE/EANM/HFSA/ISA/SCMR/SNMMI Expert Consensus Recommendations for Multimodality Imaging in Cardiac Amyloidosis: Part 1 of 2â€"Evidence Base and Standardized Methods of Imaging. Journal of Cardiac Failure, 2022, 28, e1-e4.	0.7	8
70	New approach for quantification of left ventricular function from low-dose gated bloodpool SPECT: Validation and comparison with conventional methods in patients. Journal of Nuclear Cardiology, 2021, 28, 939-950.	1.4	7
71	Quantitation of Poststress Change in Ventricular Morphology Improves Risk Stratification. Journal of Nuclear Medicine, 2021, 62, 1582-1590.	2.8	7
72	Machine learning to predict abnormal myocardial perfusion from pre-test features. Journal of Nuclear Cardiology, 2022, 29, 2393-2403.	1.4	7

#	Article	IF	Citations
73	Optimal interpretation of Tc99m PYP in 2020: Avoiding the million-dollar mistake. Journal of Nuclear Cardiology, 2021, 28, 503-506.	1.4	6
74	Comparison of diabetes to other prognostic predictors among patients referred for cardiac stress testing: A contemporary analysis from the REFINE SPECT Registry. Journal of Nuclear Cardiology, 2022, 29, 3003-3014.	1.4	6
75	Risk and predictors of mortality after implantable cardioverter-defibrillator implantation in patients with sarcoid cardiomyopathy. American Heart Journal, 2022, 246, 21-31.	1.2	6
76	Partial Liver Kinase B1 (LKB1) Deficiency Promotes Diastolic Dysfunction, De Novo Systolic Dysfunction, Apoptosis, and Mitochondrial Dysfunction With Dietary Metabolic Challenge. Journal of the American Heart Association, 2016, 5, .	1.6	5
77	Quantification and Determination of Normal ¹²³I-Meta Iodobenzylguanidine Heart-to-Mediastinum Ratio (HMR) from Cardiac SPECT/CT and Correlation with Planar HMR. Journal of Nuclear Medicine, 2018, 59, 652-658.	2.8	5
78	Feasibility study of PET dynamic imaging of [18F]DHMT for quantification of reactive oxygen species in the myocardium of large animals. Journal of Nuclear Cardiology, 2022, 29, 216-225.	1.4	5
79	Biobank Scale Pharmacogenomics Informs the Genetic Underpinnings of Simvastatin Use. Clinical Pharmacology and Therapeutics, 2021, 110, 777-785.	2.3	5
80	Non-steroidal treatment of cardiac sarcoidosis: A systematic review. IJC Heart and Vasculature, 2021, 34, 100782.	0.6	5
81	Quantitative interpretation of FDG PET for cardiac sarcoidosis reclassifies visually interpreted exams and potentially impacts downstream interventions. Sarcoidosis Vasculitis and Diffuse Lung Diseases, 2018, 35, 342-353.	0.2	5
82	Imaging Options in Cardiac Amyloidosis: Differentiating AL from ATTR. Current Cardiovascular Imaging Reports, 2017, 10, 1.	0.4	4
83	Incidental finding of COVID-19 pulmonary infiltrates on SPECT/CT attenuation correction CT. Journal of Nuclear Cardiology, 2020, 27, 1385-1386.	1.4	4
84	Radiopharmaceutical supply disruptions and the use of 99mTc-hydroxymethylene diphosphonate as an alternative to 99mTc-pyrophosphate for the diagnosis of transthyretin cardiac amyloidosis: An ASNC Information Statement. Journal of Nuclear Cardiology, 2022, 29, 2748-2760.	1.4	4
85	Impact of the ISCHEMIA Trial on Stress Nuclear Myocardial Perfusion Imaging. Journal of Nuclear Medicine, 2020, 61, 962-964.	2.8	3
86	Prevalence and predictors of automatically quantified myocardial ischemia within a multicenter international registry. Journal of Nuclear Cardiology, 2022, 29, 3221-3232.	1.4	3
87	AMPK â€“ A pivotal rheostat in the control of cardiac metabolism. Drug Discovery Today Disease Mechanisms, 2005, 2, 93-100.	0.8	2
88	An unusual case of nonbacterial thrombotic (marantic) endocarditis. Journal of Thoracic and Cardiovascular Surgery, 2009, 137, 239-241.	0.4	2
89	Quantifying FDG uptake to diagnose cardiac device infections: When and how should we do it?. Journal of Nuclear Cardiology, 2016, 23, 1467-1469.	1.4	2
90	Use of fluorine-18 sodium fluoride for the diagnosis of transthyretin cardiac amyloidosis: The birth of a new technique. Journal of Nuclear Cardiology, 2018, 25, 1568-1570.	1.4	2

#	Article	IF	Citations
91	Using FDG-PET to guide targeted cardiac magnetic resonance imaging in patients with suspected cardiac sarcoidosis. Journal of Nuclear Cardiology, 2020, 27, 688-690.	1.4	2
92	Impaired Myocardial Flow Reserve on ⁸²Rubidium Positron Emission Tomography/Computed Tomography in Patients With Systemic Sclerosis. Journal of Rheumatology, 2021, 48, 1574-1582.	1.0	2
93	Cytokine Signaling and Matrix Remodeling Pathways Associated with Cardiac Sarcoidosis Disease Activity Defined Using FDG PET Imaging. International Heart Journal, 2021, 62, 1096-1105.	0.5	2
94	Calcium scoring in low-dose ungated chest CT scans using convolutional long-short term memory networks. , 2022, , .		2
95	Differences in Prognostic Value of Myocardial Perfusion Single-Photon Emission Computed Tomography Using High-Efficiency Solid-State Detector Between Men and Women in a Large International Multicenter Study. Circulation: Cardiovascular Imaging, 2022, 15, .	1.3	2
96	Diagnosis of extensive myocardial infiltration by diffuse large B-cell lymphoma using 18F-fluorodeoxyglucose positron emission tomography (18-FDG PET). Journal of Nuclear Cardiology, 2018, 25, 1869-1871.	1.4	1
97	Complex cellular physiology underlies the use of FDG-PET imaging in investigating post-infarction remodeling. Journal of Nuclear Cardiology, 2020, 27, 532-533.	1.4	1
98	Potential novel imaging targets of inflammation in cardiac sarcoidosis. Journal of Nuclear Cardiology, 2022, 29, 2171-2187.	1.4	1
99	Can We Manage Presymptomatic TTRÂV142I Related Risk?. JACC: Heart Failure, 2022, 10, 139-141.	1.9	1
100	The integration of genetically-regulated transcriptomics and electronic health records highlights a pattern of medical outcomes related to increased hepatic transthyretin expression. Amyloid: the International Journal of Experimental and Clinical Investigation: the Official Journal of the International Society of Amyloidosis, 2022, 29, 110-119.	1.4	1
101	MIF in Cardiovascular Disease. , 2012, , 347-358.		0
102	Multimodality Imaging of Cardiac Sarcoidosis. , 2015, , 51-72.		0
103	New Method for Quantification of the Left Ventricular Function from Low-dose Equilibrium Radionuclide Angiocardiography: Comparisons with Conventional Methods in Patients. , 2018, , .		0
104	Advanced Cardiac Imaging and the Complexity of Diagnosing Cardiac Sarcoidosis. Circulation: Cardiovascular Imaging, 2019, 12, e009275.	1.3	0
105	Cardiac Sarcoidosis. , 2019, , 105-113.		0
106	Quantification of myocardial blood flow (MBF) and reserve (MFR) incorporated with a novel segmentation approach: Assessments of quantitative precision and the lower limit of normal MBF and MFR in patients. Journal of Nuclear Cardiology, 2021, 28, 1236-1248.	1.4	0
107	Evaluation of Chest Pain. , 2014, , 3-13.		0